<DOC>
	<DOCNO>NCT00391924</DOCNO>
	<brief_summary>The purpose study examine whether dehydroepiandrosterone ( DHEA ) administration improve fatigue general well-being patient systemic lupus erythematosus primary Sjögren 's syndrome</brief_summary>
	<brief_title>Dehydroepiandrosterone Administration Women With Systemic Lupus Erythematosus Primary Sjögren 's Syndrome</brief_title>
	<detailed_description>Fatigue reduce general well-being frequent complaint patient chronic autoimmune disorder systemic lupus erythematosus ( SLE ) primary Sjögren 's syndrome ( pSS ) . Uncontrolled study suggest administration dehydroepiandrosterone ( DHEA ) may improve complaint . The aim randomize double-blind placebo-controlled study examine effect daily oral 200 mg DHEA fatigue , well-being , function woman SLE pSS .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Sjogren 's Syndrome</mesh_term>
	<mesh_term>Dehydroepiandrosterone</mesh_term>
	<criteria>pSS focus score &gt; = 1 minor salivary gland biopsy fulfil European classification criterion ( Ann Rheum Dis 1996 ; 55:11621 ) SLE accord ACR classification criterion ( Arthritis Rheum 1982 ; 25:12717 ) Willingness apply effective contraception ( premenopausal woman ) Written informed consent . Pregnancy Pregnancy wish Serum creatinine &gt; 150 µmol/L Glucocorticoid use daily dose &gt; 10 mg prednisone ( equivalent ) Cyclophosphamide treatment precede year Hyper hypothyroidism History malignancy within previous 5 year exception squamous basal cell carcinoma skin</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2006</verification_date>
	<keyword>Dehydroepiandrosterone</keyword>
	<keyword>Fatigue</keyword>
	<keyword>Quality life</keyword>
	<keyword>Lupus Erythematosus , Systemic</keyword>
	<keyword>Sjogren 's Syndrome</keyword>
	<keyword>Bone mineral density</keyword>
</DOC>